ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2026
Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbiota-gut-brain axis dysfunction is increasingly implicated in the development of various neuropathologies. The blood-brain barrier (BBB) serves as a critical interface between the central nervous system (CNS) and the systemic milieu, modulated by the gut microbiota and associated secretome. Increasingly, the therapeutic potential of microbial metabolites, such as short-chain fatty acids (SCFAs), in reducing BBB disruption and mitigating neuropathologies across multiple neurological conditions has been explored. However, research methodologies remain inconsistent, owing to a lack of clarity on how to effectively model microbiota-gut-brain interactions at the BBB interface. In order to fully realise the potential of the microbiota-gut-brain axis it is crucial to adopt best-practice study designs alongside ongoing advancements in biotechnology that enable more biologically relevant modelling of this complex system. In this review, we examine current knowledge on the role of the BBB in mediating microbiota-gut-brain interactions and explore both established and emerging methods used to study these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.